Back to Journals » OncoTargets and Therapy » Volume 10
Original Research
Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
7,729 | Dovepress* | 7,116+ | 1,470 | 8,586 | |
PubMed Central* | 613 | 269 | 882 | ||
Totals | 7,729 | 1,739 | 9,468 | ||
*Since 18 January 2017 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
4 | 0 | 0 | 0 | 2 | 2 |
View citations on PubMed Central and Google Scholar